Innate Pharma (IPHYF) Non-Current Debt (2017 - 2025)

Innate Pharma's Non-Current Debt history spans 9 years, with the latest figure at $16.0 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 32.69% year-over-year to $16.0 million; the TTM value through Dec 2025 reached $16.0 million, down 32.69%, while the annual FY2025 figure was $16.0 million, 33.54% down from the prior year.
  • Non-Current Debt reached $16.0 million in Q4 2025 per IPHYF's latest filing, down from $23.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $41.0 million in Q4 2022 to a low of $15.4 million in Q4 2021.
  • Average Non-Current Debt over 5 years is $25.9 million, with a median of $23.8 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: skyrocketed 165.18% in 2022, then crashed 32.69% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $15.4 million in 2021, then surged by 165.18% to $41.0 million in 2022, then fell by 18.69% to $33.3 million in 2023, then fell by 28.5% to $23.8 million in 2024, then plummeted by 32.69% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Non-Current Debt are $16.0 million (Q4 2025), $23.8 million (Q4 2024), and $33.3 million (Q4 2023).